Argos Therapeutics Inc. (historically traded under ticker ARGS, with over-the-counter quotes under ARGSQ) trades at approximately $0.05 per share, reflecting a micro-capitalization profile typical of distressed or liquidated equities. The equity sits near the lower bound of its historical trading spectrum, backed by a minimal market capitalization as the clinical-stage biopharmaceutical firm navigated prior restructuring events, financial distress, and strategic asset wind-downs. Retail investors and market participants tracking legacy biotechnology listings must exercise extreme caution due to restricted liquidity, limited public disclosures, and minimal trading volumes on over-the-counter exchanges.